Welcome to GSK’s product website

Here you will find information about GSK’s medicines and vaccines

I’m a UK healthcare professional

Important notice: this site is intended for UK healthcare professionals. By entering this site, you are confirming that you are a UK healthcare professional. This site may contain promotional information.

I’m a member of the UK public

This site is intended for members of the UK public, patients and their carers.

M.C. Last updated: March 2018. UK/COM/0106/15(2)

M.C. Last updated: March 2018. UK/COM/0106/15(2)

What is Anoro Ellipta?


Indication

Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD1.

Dosing

The recommended and maximum dose of Anoro Ellipta (UMEC/VI 55/22 mcg) is one inhalation once a day. If a dose is missed the next dose should be taken at the usual time the next day1.

MeetHannah*

  • AGE: 56
  • mMRC2 : 2
  • CAT SCORE : 10
  • FEV1 predicted: 65%
  • GOLD PATIENT GROUP: B
  • EXACERBATION HISTORY: None within the last 12 months
  • SYMPTOMS: Breathless on exertion, walks slower than others her age
  • HANNAH IS STILL BREATHLESS DESPITE AS-NEEDED SABA**
* Fictional patient
** Short-acting beta2 agonist

Which maintenance medication would you start Hannah on?

Anoro vs.
LAMA alone

50% of patients with COPD still experience breathlessness on monotherapy3.

LAMA/LABAs demonstrate superior lung function and symptom improvements vs monotherapy4.

A pooled, post hoc subgroup analysis showed that in patients naive to COPD maintenance therapy, Anoro has demonstrated a 2.4x greater improvement in lung function vs tiotropium HandiHaler with a comparable safety profile5,6.

Start with Anoro. It could provide you and your patients a superior alternative to LAMA alone5,6.

Details of the blinding process for all tiotropium HandiHaler comparator studies discussed on this page can be found on page 474 in Decramer M at al. Lancet Respir Med 2014; 2:472-4867.

Think all
LAMA/LABAs
are the same?

Anoro is the only once-daily LAMA/LABA to demonstrate in-class superiority8.

In a head-to-head trial, Anoro Ellipta provided 1.4x superior lung function improvement vs Spiolto, another LAMA/LABA8.

Anoro also provided a 38% reduction in rescue medication usage vs Spiolto. The safety profiles were comparable between Spiolto and Anoro8.

Prescribe Anoro for superior lung function improvement compared with Spiolto8.

Anoro comes in the easy to use Ellipta inhaler9-11

Looking to review the guidelines in your local health economy?

Value.GSK

Value.GSK

Find out more with tailored information about Anoro and the other Ellipta devices on a portal for commissioners


Go to Value.GSK
formulary

Formulary

Information to support commissioners and healthcare professionals when making an Anoro formulary application


View evidence summary

Get started with Anoro Ellipta
for patients with COPD like Hannah

COPD assessment test (CAT) pad

Identify patients like Hannah using the CAT score pad

COPD assessment test (CAT) pad questionnaire to measure the impact of COPD on a person’s life.

Order now
Ellipta inhalation trainer

Can your patient use the Ellipta device effectively?

Ellipta inhalation training whistle that helps patients understand the correct inspiratory flow needed to use the Ellipta device.

Order now
Ellipta demonstration device

Help demonstrate the Ellipta device to patients like Hannah

Ellipta Demonstration device for healthcare professionals to show patients how to use the Ellipta device correctly.

Order now

References

  • 1. Anoro SmPC
  • 2. Stenton et al. Occupational Medicine; 2008: 58:226–227
  • 3. Müllerová, H., et al., PLOS ONE, 2014. 9(1). p. e85540.
  • 4. Oba Y et al. Thorax 2016; 71:15-25.
  • 5. Maleki-Yazdi M et al. Adv Ther 2016; 33:2188-2199.
  • 6. GSK DATA on file: RF/UCV/0112/15(1).
  • 7. Decramer M et al. Lancet Respir Med 2014; 2:472-486.
  • 8. Feldman G.J. et al. Adv Ther 2017; 34:doi 10.1007/s12325-017-0626-4.
  • 9. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873-1880.
  • 10. Svedsater H et al. BMC pulm Med 2013; 13:72-86.
  • 11. Van der Palen J et al. NPJ Primare Respir Med 2016; 26:16079.
innoviva_logo

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Anoro and Ellipta are registered trademarks of the GlaxoSmithKline group of companies

I.H. Last updated: October 2018. UK/UCV/0025/18